700 Saginaw Drive
60 articles with Revolution Medicines
Revolution Medicines Presents Data from its SHP2 and Oncogenic RAS(ON) Programs at 6th AACR-IASLC International Joint Conference
Revolution Medicines, Inc., today announced that preliminary data from the company's Phase 1 clinical trial (RMC-4630-01) of RMC-4630 were reported in podium and poster presentations at the 6th AACR-IASLC International Joint Conference: Lung Cancer Translational Science
Revolution Medicines to Present Preliminary Data from Phase 1 Clinical Trial of RMC-4630 at 6th AACR-IASLC International Joint Conference
Podium and Poster Presentations to Highlight Initial Findings from Monotherapy Study of Investigational SHP2 Inhibitor, RMC-4630 Additional Poster Presentation to Report New Preclinical Results for Company's Novel Inhibitors of Oncogenic RAS(ON) mutants
Revolution Medicines and Amgen Partner on Phase 1b Study to Evaluate Combination of RMC-4630 and AMG 510
Study to Evaluate Combination of Investigational SHP2 and KRASG12C Inhibitors in Patients with KRASG12C Mutant Advanced Solid Tumors
Revolution Medicines to Present Preclinical Data on Novel Inhibitors of Oncogenic RAS(ON) Mutants at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Revolution Medicines, Inc., a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways, today announced that preclinical in vivo data on the company's novel inhibitors of oncogenic RAS(ON) mutants will be presented at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
REVOLUTION Medicines Closes $100 Million Financing to Advance Pipeline of Novel Therapies Addressing Frontier Targets in RAS-Dependent Cancers
Lead Clinical Candidate Targeting SHP2 Currently in Phase 1/2 Clinical Program for Tumors with Specific Oncogenic Mutations
Bay Area-based Revolution Medicines Inc. secured $100 million in Series C financing that will be used to support the development of the company’s pipeline of drugs that target the RAS pathway, including its lead clinical candidate.
Ginkgo Bioworks Acquires Warp Drive Bio's Genome Mining Platform for Discovery and Development of Novel Classes of Antibiotics
Acquisition expands Ginkgo's biological codebase for organism engineering for the production of natural product pharmaceuticals
REVOLUTION Medicines, Inc., a biotechnology company that translates frontier oncology targets to outsmart cancer, today announced that it will make a presentation at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
REVOLUTION Medicines Acquires Warp Drive Bio to Expand Drug Discovery Portfolio Focused on Frontier Oncology Targets
REVOLUTION Medicines, Inc. and Warp Drive Bio, Inc. announced today that REVOLUTION Medicines is acquiring Warp Drive Bio.
REVOLUTION Medicines Announces First Patient Dosed with RMC-4630 in Phase 1 Clinical Study in Patients with Advanced Solid Tumors
Scientific publication reports preclinical results showing precision oncology opportunity for targeting SHP2 in genetically selected tumors
Sanofi and REVOLUTION Medicines Launch Global Partnership to Develop Potential First-in-Class Targeted Treatments for Multiple Cancers
Preclinical studies of SHP2 inhibitors demonstrated promise across multiple forms of cancer; lead drug candidate expected to start clinical trials in second half of 2018.
In April Bay Area biotech Revolution Medicines completed its pivot from a company focused on antifungal treatments to an oncology business. This morning Revolution’s shift paid off with a development deal worth up to $500 million with Sanofi.
Revolution Medicines Raises Another $56 Million and Completes Pivot from Antifungal to Cancer Com...
4/24/2018Revolution Medicines closed on a Series B financing round worth $56 million. The round was led by Nextech Invest, with participation from Casdin Capital, Schroder Adveq, The Column Group, Third Rock Ventures and undisclosed institutional investors.
REVOLUTION Medicines, Inc. announced it has raised $56 million in a Series B financing to support its ongoing R&D programs and general business activities.
Revolution Medicines Appoints Cancer Leader Dr. Stephen Kelsey As President Of Research And Development
Revolution Medicines Names Academic Co-Founder, Michael Fischbach, Ph.D., And Senior Advisor, Eric Gordon, Ph.D.
Rationally Designed Antifungal Compounds That Evade Resistance Reported In Nature Chemical Biology By Scientific Founder Of Revolution Medicines
Revolution Medicines Appoints Pharmaceutical Commercial Executive Elizabeth McKee Anderson To Board Of Directors